دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Table of Contents
doi : 10.1016/S0923-7534(23)04243-6
Volume 34, Issue 11, November 2023, Pages i-ii
ctDNA as a predictive biomarker in advanced breast cancer: Lessons from the MONALEESA studies
doi : 10.1016/j.annonc.2023.09.3111
Volume 34, Issue 11, November 2023, Pages 955-959
Standard versus prolonged intervals to surgery in resectable esophageal cancer: does timing matter?
S. Derks 1,2,3 * & H. W. M. van Laarhoven 2
doi : 10.1016/j.annonc.2023.09.3105
Volume 34, Issue 11, November 2023, Pages 960-961
Time to start testing KRAS and BRAF V600E mutations in stage III colon cancer? Not in routine care, yet in clinical trials
R. Dienstmann PhD
doi : 10.1016/j.annonc.2023.10.002
Volume 34, Issue 11, November 2023, Pages 962-963
Optimizing the potential of antibody–drug conjugates in oncology
F. Mosele 1,2 *, G. Montagnac 3 , B. Pistilli1 & F. André
doi : 10.1016/j.annonc.2023.08.020
Volume 34, Issue 11, November 2023, Pages 964-967
Moving towards tissue-agnostic antibody drug conjugates: HER2 expression as the poster child
R. Abelman, L. M. Spring, R. Corcoran & A. Bardia* Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
doi : 10.1016/j.annonc.2023.10.115
Volume 34, Issue 11, November 2023, Pages 968-969
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
G. Curigliano 1,2y, H. J. Burstein3,4y, M. Gnant5,6 , S. Loibl 7,8 , D. Cameron9 , M. M. Regan10 , C. Denkert 11 , P. Poortmans 12,13 , W. P. Weber 14,15 & B. Thürlimann16,17 , St Gallen Consensus Conference Panelists 2023
doi : 10.1016/j.annonc.2023.08.017
Volume 34, Issue 11, November 2023, Pages 970-986
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
T. Conroy1,2 , P. Pfeiffer3 , V. Vilgrain 4,5 , A. Lamarca 6 , T. Seufferlein7 , E. M. O’Reilly 8 , T. Hackert 9 , T. Golan 10 , G. Prager11 , K. Haustermans12 , A. Vogel13 & M. Ducreux14 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2023.08.009
Volume 34, Issue 11, November 2023, Pages 987-1002
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
F. André 1, F. Su 2 , N. Solovieff 3 , G. Hortobagyi4 , S. Chia5 , P. Neven6 , A. Bardia7 , D. Tripathy4 , Y.-S. Lu8 , A. Lteif2 , T. Taran9 , N. Babbar 2 , D. Slamon10 & C. L. Arteaga
doi : 10.1016/j.annonc.2023.08.011
Volume 34, Issue 11, November 2023, Pages 1003-1014
Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial
K. Nilsson 1,2 , F. Klevebro1,2 , B. Sunde 1,2 , I. Rouvelas 1,2 , M. Lindblad1,2 , E. Szabo3 , I. Halldestam 4 , U. Smedh5 , B. Wallner 6 , J. Johansson 7 , G. Johnsen 8 , E. K. Aahlin 9 , H.-O. Johannessen10 , G. Alexandersson von D?beln2,11 , G. O. Hjortland 12 , N. Wang 13 , Y. Shang14 , D. Borg15 , A. Quaas 16 , I. Bartella17 , C. Bruns17 , W. Schr?der17 & M. Nilsson
doi : 10.1016/j.annonc.2023.08.010
Volume 34, Issue 11, November 2023, Pages 1015-1024
Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials
J. Taieb1,2, F. A. Sinicrope 2y, L. Pederson3 , S. Lonardi 4 , S. R. Alberts2 , T. J. George 5 , G. Yothers 6 , E. Van Cutsem7 , L. Saltz 8 , S. Ogino 9 , R. Kerr 10 , T. Yoshino11 , R. M. Goldberg12,13 , T. André14 , P. Laurent-Puig 15,16,17y & Q. Shi
doi : 10.1016/j.annonc.2023.08.006
Volume 34, Issue 11, November 2023, Pages 1025-1034
HER2-low expression in patients with advanced or metastatic solid tumors
B. Uzunparmak1 , C. Haymaker 2 , G. Raso2 , S. Masciari 3 , L. Wang3 , H. Lin 4 , A. Gorur 1 , B. Kirby1 , A.-M. Cimo 1 , A. Kennon1 , Q. Ding5 , G. Urschel 1 , Y. Yuan 4 , G. Feng 1 , Y. Rizvi 1 , A. Hussain1 , C. Zhu3 , P. Kim 3 , G. Abbadessa 3 , V. Subbiah 1 , T. A. Yap1,6,7 , J. Rodon1,7,8 , S. A. Piha-Paul1 , F. Meric-Bernstam 1,7,9 & E. E. Dumbrava
doi : 10.1016/j.annonc.2023.08.005
Volume 34, Issue 11, November 2023, Pages 1035-1046
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆
J. E. Rosenberg1y, T. Powles2y, G. P. Sonpavde3 , Y. Loriot 4 , I. Duran 5 , J.-L. Lee 6 , N. Matsubara 7 , C. Vulsteke8 , D. Castellano9 , R. Mamtani 10 , C. Wu 11 , M. Matsangou 12 , M. Campbell 13 & D. P. Petrylak
doi : 10.1016/j.annonc.2023.08.016
Volume 34, Issue 11, November 2023, Pages 1047-1054
Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas
Y. Song 1 , D. H. Yoon2 , H. Yang 3 , J. Cao4 , D. Ji 4 , Y. Koh5 , H. Jing 6 , H. Eom7 , J. Kwak 8 , W. Lee9 , J. Lee10 , H. Shin 11 , J. Jin 12 , M. Wang 13 , Z. Yang13 , W. S. Kim 14 & J. Zhu
doi : 10.1016/j.annonc.2023.08.013
Volume 34, Issue 11, November 2023, Pages 1055-1063
High incidence of cytokine release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumab
Y. Shiraishi 1 , Y. Sekino 2 , H. Horinouchi 3 , Y. Ohe 3 & I. Okamoto
doi : 10.1016/j.annonc.2023.08.012
Volume 34, Issue 11, November 2023, Pages 1064-1065
Off-target resistance to larotrectinib in two patients with NTRK fusion-positive pediatric solid tumors
S. Lu 1,2,y, W. Xie 1,2,y, Y. Zhang1,2 , F. Sun 1,2 , J. Huang 1,2 , J. Wang 1,2 , J. Zhu 1,2 , Z. Zhen 1,2 & Y. Zhang
doi : 10.1016/j.annonc.2023.08.015
Volume 34, Issue 11, November 2023, Pages 1065-1067
